Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON-PFT Extension 1
NCT00145327Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2005
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid in osteoporosis (3 arms), sponsored by Novartis. Primary endpoint: Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3. Started May 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00145327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145327.